布拉格治疗联合维迪西妥单抗治疗HER2低表达的难治性乳腺癌1例  

Refractory breast cancer with low HER2 expression was treated with PRaG regimen in combination with Disitamab Vedotin:a case report

作　　者：杨梦梦 赵向荣 陈光强[2] 张力元[1] Yang Mengmeng;Zhao Xiangrong;Chen Guangqiang;Zhang Liyuan(Center of PRaG Therapy,Center for Cancer Diagnosis and Treatment,Laboratory of Cancer Radioimmunotherapy,the Second Affiliated Hospital of Soochow University Suzhou 215004,China;Department of Imaging Diagnosis,the Second Affiliated Hospital of Soochow University,Suzhou 215004,China)

机构地区：[1]苏州大学附属第二医院布拉格治疗中心,苏州大学附属第二医院肿瘤诊疗中心,苏州大学附属第二医院肿瘤放射免疫治疗实验室,苏州215004 [2]苏州大学附属第二医院影像诊断科,苏州215004

出　　处：《中华转移性肿瘤杂志》2024年第3期252-255,共4页Chinese Journal of Metastatic Cancer

基　　金：省部共建放射医学与辐射防护国家重点实验室内部协作课题(GZN1202302);中国宝原投资有限公司科研项目(270004);中核医疗“核医科技创新”项目(ZHYLTD2021001)。

摘　　要：复发转移是晚期乳腺癌死亡的主要原因,人表皮生长因子受体2低表达型患者的治疗手段有限,布拉格治疗是一种新型的放免联合治疗模式。本文报道了1例术后、化疗后、内分泌治疗后多发转移的乳腺癌患者采用布拉格治疗12个周期后,乳腺相关肿瘤标志物下降至正常范围,疗效评估为部分缓解,无进展生存期达29个月,现定期随访中。The main causes of death of advanced breast cancer are recurrence and metastasis.The treatment of patients with low human epidermal growth factor receptor 2(HER2)expression is limited.PRaG regimen is a new type of combined radioimmunotherapy mode.A patient of breast cancer with multiple metastases after surgery,chemotherapy and endocrine therapy was now reported.After 12 cycles of PRaG regimen,the tumor markers for breast cancer decreased to the normal range.The efficacy was assessed as a partial response,and progression-free survival was up to 29 months.Now regular follow-up is continued as planned.

关 键 词：乳腺癌 肺转移癌 人表皮生长因子受体2 布拉格治疗 

分 类 号：R737.9[医药卫生—肿瘤]